Key Points
- Insider sales: Major shareholder Chidozie Ugwumba sold a total of 153,959 shares of Clene between Jan 8–23 for about $806,597, and his Jan 23 sale left him with 599,603 shares valued at roughly $3.16M (a 0.92% ownership decrease after the latest sale).
- Company context: Clene is a clinical‑stage biopharmaceutical (lead candidate CNM‑Au8) with a market cap of ~$57.6M, negative earnings, a 12‑month range of $2.28–$13.50, and a MarketBeat consensus of "Moderate Buy" with an average price target of $32.60.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 5,556 shares of the firm's stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $5.27, for a total transaction of $29,280.12. Following the transaction, the insider directly owned 599,603 shares of the company's stock, valued at $3,159,907.81. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total transaction of $67,377.80.
- On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The stock was sold at an average price of $5.05, for a total transaction of $61,200.95.
- On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total value of $59,673.60.
- On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total value of $40,644.99.
- On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total value of $64,071.30.
- On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total value of $100,459.52.
- On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total value of $127,653.45.
- On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total value of $179,877.50.
- On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $56,900.25.
- On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total transaction of $19,457.55.
Clene Stock Performance
CLNN opened at $5.31 on Friday. The firm has a market cap of $57.61 million, a price-to-earnings ratio of -1.57 and a beta of 0.87. The firm's 50-day simple moving average is $6.75 and its 200-day simple moving average is $6.49. Clene Inc. has a twelve month low of $2.28 and a twelve month high of $13.50.
Clene (NASDAQ:CLNN - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.06 million. As a group, sell-side analysts anticipate that Clene Inc. will post -5.19 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on CLNN. Benchmark reaffirmed a "buy" rating on shares of Clene in a report on Thursday, December 4th. UBS Group restated a "buy" rating on shares of Clene in a report on Wednesday, December 3rd. D. Boral Capital reaffirmed a "buy" rating and issued a $23.00 price target on shares of Clene in a report on Friday, January 9th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Clene in a research report on Friday, January 9th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $32.60.
View Our Latest Report on CLNN
Hedge Funds Weigh In On Clene
Several large investors have recently made changes to their positions in CLNN. Lunt Capital Management Inc. boosted its holdings in Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock valued at $199,000 after acquiring an additional 21,217 shares during the last quarter. Jane Street Group LLC bought a new stake in Clene during the 2nd quarter worth about $47,000. Scoggin Management LP lifted its position in Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company's stock valued at $558,000 after purchasing an additional 42,750 shares during the period. Finally, Jones Financial Companies Lllp acquired a new position in Clene during the 3rd quarter valued at about $29,000. Institutional investors and hedge funds own 23.28% of the company's stock.
Clene Company Profile
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
